Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Relief Claims OK’ed for 54 More Deaths after COVID Vaccination
September 4, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- MHLW Rejigs Organization, Infectious Disease Control Team Boots Up
September 1, 2023
- Industry Requests Rewards for SaMDs that Help Doctors’ Workstyle Reform
September 1, 2023
- Japan to Decide on COVID Health Funding from October, Assuming Shift to Normalcy Next Spring: Minister
September 1, 2023
- MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
- 8 New Cases of Unintentional Xocova Use Among Pregnant Patients, Adding Up to 15
August 31, 2023
- Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
- MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
August 31, 2023
- MHLW to Unveil Draft of 2nd Package Strategy for SaMD on Sept. 6
August 31, 2023
- MHLW to Issue Development Requests for New Uses of Rituxan, Truvada, and More
August 31, 2023
- Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
August 30, 2023
- MHLW Orders Label Revisions for Prazaxa, Smyraf, and More
August 30, 2023
- MHLW Panel OKs Inclusion of 5-in-1 Vaccine in National Immunization Program
August 30, 2023
- Label Revisions Ordered for CAR-T Therapies on Out-of-Spec Products
August 30, 2023
- Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
- Kazunari Asanuma to Lead MHLW Health Policy Bureau
August 29, 2023
- MHLW to Seek Funds for Survey to Streamline Generic Manufacturing: FY2024 Request
August 28, 2023
- MHLW to Book Budget to Launch Regulatory Advisory Center for Pediatric, Orphan Meds for FY2024
August 28, 2023
- MHLW to Seek 33.7 Trillion Yen Budget for FY2024
August 28, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…